Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer

References

• Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al., Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi:10.1056/NEJMoa2001191.
   PubMed Web of Science ®Google Scholar
• Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:10.1016/S1470-2045(20)30096-6.
   PubMed Web of Science ®Google Scholar
• Desai A, Gupta R, Advani S, et al. Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies. Cancer. 2020. doi:10.1002/cncr.33386.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2020. doi:10.1001/jamaoncol.2020.6178.
   Web of Science ®Google Scholar
• Desai A, Kuderer NM, Lyman GH. Crowdsourcing in crisis: rising to the occasion. JCO Clin Cancer Inform. 2020;4:551–554. doi:10.1200/CCI.20.00054.
   PubMed Web of Science ®Google Scholar
• Desai A, Warner J, Kuderer N, Thompson M, Painter C, Lyman G, et al. Crowdsourcing a crisis response for COVID-19 in oncology. Nat Cancer. 2020;1(5):473–476. doi:10.1038/s43018-020-0065-z.
   Google Scholar
• Leask H. From a tweet to the Lancet in 10 weeks: COVID-Cancer Consortium. Medscape. 2020.
   Google Scholar
• Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al., COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–1918. doi:10.1016/S0140-6736(20)31187-9.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Wulff-Burchfield E, Rubinstein SM, Grivas P, Warner JL. Cancer and COVID-19 – authors' reply. Lancet. 2020;396(10257):1067–1068. doi:10.1016/S0140-6736(20)32065-1.
   PubMed Web of Science ®Google Scholar
• Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, et al., COVID-19 and Cancer Consortium. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. 2020;10(10):1514–1527. doi:10.1158/2159-8290.CD-20-0941.
   PubMed Web of Science ®Google Scholar
• Wise-Draper TM, et.al. Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: a CCC19 registry analysis. Paper presented at: the European Society of Medical Oncology Annual Meeting; 2020.
   Google Scholar
• Grivas P, Warner J, Shyr Y, Shah D, Rubinstein SM, Kuderer NM, et al. Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: the COVID-19 and Cancer Consortium (CCC19). Paper presented at: European Society of Clinical Oncology Annual Meeting; 2020. p. LBA72.
   Google Scholar
• Kuderer NM, Lyman GH. COVID-19, cancer, and consequences: where are we now? Cancer Invest. 2020;38(8-9):431–435. doi:10.1080/07357907.2020.1812174.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Administration UFaD. Pfizer-BioNTech COVID-19 Vaccine. US Food and Drug Administration; 2020.
   Google Scholar
• Administration UFaD. FDA briefing document. Vaccines and Related Biological Products Advisory Committee Meeting; 2020 Dec 10. Available from: https://www.fda.gov/media/144245/download
   Google Scholar
• Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2020. doi:10.1056/NEJMra2035343.
   Web of Science ®Google Scholar
• Mahase E. Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy. BMJ. 2020;371:m4709. doi:10.1136/bmj.m4709.
   PubMedGoogle Scholar
• Administration UFaD. Vaccines and Related Biological Products Advisory Committee Meeting; 2020 Dec 17. Available from: https://www.fda.gov/media/144434/download
   Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al., mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–2438. doi:10.1056/NEJMoa2028436.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416.
   PubMed Web of Science ®Google Scholar
• Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80–82. doi:10.1056/NEJMc2032195.
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493–504. doi:10.1016/S1473-3099(09)70175-6.
   PubMed Web of Science ®Google Scholar
• Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL, Lee JY. Influenza immunization of adult patients with malignant diseases. Ann Intern Med. 1977;87(5):552–557. doi:10.7326/0003-4819-87-5-552.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Dhodapkar KM, Ahmed R. Viral immunity and vaccines in hematologic malignancies: implications for COVID-19. Blood Cancer Discov. 2021;2(1):9–12. doi:10.1158/2643-3230.BCD-20-0177.
   PubMedGoogle Scholar
• Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34(11):3047–3049. doi:10.1038/s41375-020-01030-2.
   PubMed Web of Science ®Google Scholar
• Foord AM, Cushing-Haugen KL, Boeckh MJ, Carpenter PA, Flowers MED, Lee SJ, et al. Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. Blood Adv. 2020;4(7):1232–1241. doi:10.1182/bloodadvances.2020001470.
   PubMed Web of Science ®Google Scholar
• Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64–74. doi:10.1002/art.25034.
   PubMed Web of Science ®Google Scholar
• Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Maloy M, et al. Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance. Biol Blood Marrow Transplant. 2018;24(4):871–876. doi:10.1016/j.bbmt.2017.12.795.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, et al., Type 1 Diabetes TrialNet Study Group. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol. 2011;128(6):1295–302.e5. doi:10.1016/j.jaci.2011.08.008.
   PubMed Web of Science ®Google Scholar
• Sinisalo M, Aittoniemi J, Oivanen P, Käyhty H, Olander RM, Vilpo J, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001;114(1):107–110. doi:10.1046/j.1365-2141.2001.02882.x.
   PubMed Web of Science ®Google Scholar
• van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81. doi:10.1002/art.25033.
   PubMed Web of Science ®Google Scholar
• Shadman M, Ujjani C. Vaccinations in CLL: implications for COVID-19. Blood. 2021;137(2):144–146. doi:10.1182/blood.2020009966.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Ciccolini J, Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer. 2020. doi:10.1038/s41416-020-01219-3.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200–e212. doi:10.1016/S1473-3099(18)30600-5.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Cesaro S, de Lavallade H, Di Blasi R, Einarsdottir S, Gallo G, et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e188–e199. doi:10.1016/S1473-3099(18)30601-7.
   PubMed Web of Science ®Google Scholar
• Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925–935. doi:10.1182/blood.2019004000.
   PubMed Web of Science ®Google Scholar
• Ribas A, Sengupta R, Locke T, et al. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 2020;11(2):233–236.
   PubMed Web of Science ®Google Scholar
• Committee NCCNC-VA. Preliminary recommendations of the NCCN COVID-19 Vaccination Advisory Committee. 2020.
   Google Scholar
• American Society of Hematology. ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients. 2021. Available from: https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients#.YBSMwV99dh9.twitter
   Google Scholar
• Lyman GH, Kuderer NM. Randomized controlled trials versus real-world data in the COVID-19 era: a false narrative. Cancer Invest. 2020;38(10):537–542. doi:10.1080/07357907.2020.1841922.
   PubMed Web of Science ®Google Scholar
• Gostin LO, Salmon DA, Larson HJ. Mandating COVID-19 vaccines. JAMA, 2020. doi:10.1001/jama.2020.26553.
   Web of Science ®Google Scholar
• Boo J, Matsubayashi T, Ueda M. Diurnal variation in suicide timing by age and gender: evidence from Japan across 41 years. J Affect Disord. 2019;243:366–374. doi:10.1016/j.jad.2018.09.030.
   PubMed Web of Science ®Google Scholar
• Administration UFaD. Moderna COVID-19 vaccine. US Food and Drug Administration; 2020.
   Google Scholar